Navigation Links
News brief: Knockdown of E2F1 reduces invasive potential of melanoma cells
Date:12/23/2009

Inhibition of transcription factor E2F1 reduced epidermal growth factor receptor (EGFR) expression and reduced the invasive potential but not proliferation of metastatic melanoma cells, according to a brief communication published online December 23 in the Journal of the National Cancer Institute.

To investigate E2F1's role in cancer progression, Brigitte M. Ptzer, M.D., Ph.D., of the department of vectorology and experimental gene therapy at the University Rostock in Germany, and colleagues used E2F1 gene silencing in melanoma cells and in mice to compare cell growth and invasive potential and tumor growth and formation of metastatic lesions. The authors also examined expression of EGFR, a protein previously found to be associated with cancer progression, and effects of its inhibition.

Melanoma cells with reduced E2F1 expression had lower invasive potential even though they grew at the same rate as control cells. Tumors in animals with reduced E2F1 expression grew at similar rates, but formed fewer and metastatic lesions than control tumors. EGFR expression was decreased in E2F1-silenced cells, and its inhibition reduced the invasive potential of these cells.

"Because elevated expression of E2F1 and EGFR has been observed in other tumor types, the established mechanistic link may also be important in other human cancers," the authors write. "This association should be explored in future studies."

Study limitations: Because the study was based on specific in vitro and in vivo models, it is still unclear whether these mechanisms are useful targets in human cancer.


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. News brief: Dermatologic infections in cancer patients treated with EGFRI therapy
2. News brief: Long-term testicular cancer survivors at high risk for neurological side effects
3. News brief: Estrogen receptor-alpha, breast cancer patients and tamoxifen response
4. News brief: Arsenic biomethylation required for oxidative DNA damage
5. News brief: Adverse symptom reporting by patients vs. clinicians
6. News brief: Effects of aspirin and folic acid on inflammation markers for colorectal adenomas
7. JNCI news brief: STD confirmed to be associated with increased risk of prostate cancer
8. JNCI news brief: Melanosome dynamics and sensitivity of melanoma cells to chemotherapy
9. JNCI news brief: Surgeon training found effective in breast cancer sentinel lymph node trial
10. JNCI news brief: High serum insulin levels and risk of prostate cancer
11. JNCI news brief: Antibody linked to chemotherapy drug inhibits ovarian cancer in lab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 26, 2017 , ... New SUPRO® XT55 Isolated Soy ... by helping beverage manufacturers more effectively manage protein costs. “Soy protein has always ... well as more stable pricing over time. Now it’s even more relevant as ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus ... that’s the first in a new class of photodynamic cosmetics (PDC). , Allumera® ... skin, visibly reduce outward signs of aging, and minimize the appearance of pores ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, ... cells) Phase I/II HOPE clinical trial in Duchenne announced today. , Coalition ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent ... test score performance for the 2015-16 school year across Wisconsin’s public schools, charter ... it highlights important patterns in student test score performance, the report’s limited analyses ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who ... achieves results in a fraction of the time as traditional braces – Wilckodontics®. ... Dental Specialists, now offers this revolutionary treatment with or without a referral. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
(Date:4/19/2017)... -- Global Surgical Drainage Device Market: Overview ... excess liquid and air. The fluid to be drained ... Surgical drains are used in a wide variety of ... surgery, neurosurgery, plastic surgery etc. Common use of surgical ... fluid e.g. blood or pus. Surgical drains are available ...
Breaking Medicine Technology: